CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
Best supportive care +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02187042
NCT02187042N/ACompleted
CompareCT.gov

EVALUATION OF THE IMPACT OF A THERAPY MANAGEMENT PLATFORM ON THE MANAGEMENT OF PATIENTS SUFFERING FROM ADVANCED/METASTATIC RENAL CELL CARCINOMA AND RECEIVING FIRST LINE TREATMENT WITH SUNITINIB, VERSUS STANDARD FOLLOW-UP

Pfizer·observational·Posted Jul 10, 2014·Updated Oct 24, 2019

In Brief

An observational study evaluating Best supportive care and call center for Metastatic/Advanced Renal Cell Carcinoma. Completed, enrolled 70 participants across 13 sites.

Detailed Summary

100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib (Sutent) will be inclued and followed with standard care plus a call center Principal assumption : the proportion of patients presenting with at least one grade 3 or 4 AE (whether related to sunitinib or not).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic/Advanced Renal Cell Carcinoma
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 10, 2014
Enrollment StartOct 7, 2015
Primary CompletionJul 25, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.0 years ago

Interventions

Best supportive careother

BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life

call centerother

Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.